IOL Chemicals and Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
November 08, 2023 at 05:30 am
Share
IOL Chemicals and Pharmaceuticals Limited reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported sales was INR 5,453 million compared to INR 5,414.1 million a year ago. Revenue was INR 5,524.1 million compared to INR 5,464.8 million a year ago. Net income was INR 378.7 million compared to INR 159.1 million a year ago. Basic earnings per share from continuing operations was INR 6.45 compared to INR 2.71 a year ago.
For the six months, sales was INR 11,084.8 million compared to INR 11,064.2 million a year ago. Revenue was INR 11,226.5 million compared to INR 11,166.5 million a year ago. Net income was INR 837.3 million compared to INR 505.8 million a year ago. Basic earnings per share from continuing operations was INR 14.26 compared to INR 8.62 a year ago.
IOL Chemicals and Pharmaceuticals Limited is engaged in manufacturing and selling of pharmaceutical and chemical products. The Company operates through two segments: Chemical, and Pharmaceutical. The Chemical segment produces and sells Ethyl Acetate, Iso Butyl Benzene, Acetyl Chloride, Mono Chloro Acetic Acid, Para Amino Phenol (PAP), and others. The Pharmaceutical segment produces and sells various active pharma ingredients (API) include Ibuprofen, Metformin, Fenofibrate, Lamotrigine, Clopidogrel Bisulphate, Pantoprazole, Gabapentin, Paracetamol, and others. Its API product portfolio includes Ibuprofen, Metformin HCL, Pantoprazole Sodium, Clopidogrel Bisulphate (Form II), Lamotrigine, Losartan Potassium, Levetiracetam, Paracetamol, Fenofibrate (Micronised), and Gabapentin. Its Specialty Chemical division includes Ethyl Acetate, and Acetic Anhydride. Its Ethyl Acetate is used in industries like flexible packaging, pharmaceuticals, ink, food processing, pesticides, and paint industry.